Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection

The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat

Zydus Lifesciences subsidiary Sentynl acquires BridgeBio’s Nulibry

Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder

Cadila Healthcare is now Zydus Lifesciences

Zydus unveils its ‘innovation and care’ centric corporate brand identity

Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.

Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021

ANG Lifesciences acquires Ind-Swift formulation facilities for Rs 60 cr

The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization

Eris Lifesciences planning new manufacturing facility

The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation

Astec Lifesciences 1FY22 consolidated PAT at Rs. 12.98 Cr

The company posted net profit of Rs.16.18 crores for the period ended June 30, 2020.

Eris Lifesciences reports Q4FY21 consolidated net profit of Rs. 68.24 Cr

Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021

Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease

This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease

Zydus receives FDA’s tentative approval for Dapagliflozin Tablets